EMBER-2 (J2J-MC-JZLB)

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Open at Saint-Cloud since : 22/04/2021
Target : Adult
Phase : Phase I

Trial description

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

Url of the trial

Main investigator

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contact